The Gamaleya Research Center for Epidemiology and Microbiology, which developed the world's first vaccine against coronavirus Sputnik V, has launched preclinical studies of a new drug for the prevention of COVID-19, Pharmvestnik publication reports, citing data from the public procurement website.
The new vaccine was created using a technology that differs from the one used for the first drug. The new vaccine uses the technology of virus-like particles that do not contain the genetic material of the causative agent, but mimic it instead, thus forcing the body to give an immune response to the virus infiltration.
The preclinical studies of the vaccine are being carried out on animals, and they are to be completed on November 24 — December 20, the publication said. The studies will be conducted on the basis of six institutions.
Thus, the Research Institute of Medical Primatology in the Krasnodar region will assess the immunogenicity and safety of the new vaccine on primates, RBC reports.The cost of the contract will amount to 11.6 million rubles.
Pharmvestnik failed to find contracts for pharmacokinetic and carcinogenicity studies of the drug. A relevant inquiry was sent to the Ministry of Health.
The news about the efforts of the Gamaleya Center to develop another coronavirus vaccine was reported in January of 2021, when the Ministry of Health approved a state assignment for the center to develop a vaccine based on virus-like particles. It was planned to allocate about 25 million rubles from the budget for the purpose. The development of two pharmaceutical products for COVID-19 was indicated in the same state assignment.
The Russian Ministry of Defense showed a video of the destruction of US-made M777 towed howitzers in Ukraine. The US systems were destroyed by the Russian Kub (Cube) kamikaze drone